Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Antivir Ther
    January 2021
  1. ALEJOS B, Suarez-Garcia I, Bernardino JI, Blanco JR, et al
    Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.
    Antivir Ther. 2021 Jan 20. doi: 10.3851/IMP3380.
    >> Share

  2. BIJKER R, Kumarasamy N, Kiertiburanakul S, Pujari S, et al
    An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia.
    Antivir Ther. 2021 Jan 19. doi: 10.3851/IMP3379.
    >> Share

  3. POST FA, Hamzah L
    Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?
    Antivir Ther. 2021 Jan 18. doi: 10.3851/IMP3378.
    >> Share

  4. FLORIDIA M, Masuelli G, Tassis B, Franceschetti L, et al
    Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens.
    Antivir Ther. 2021 Jan 15. doi: 10.3851/IMP3376.
    >> Share

    November 2020
  5. BRUNET L, Wyatt C, Hsu R, Mounzer K, et al
    Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.
    Antivir Ther. 2020 Nov 19. doi: 10.3851/IMP3373.
    >> Share

    September 2020
  6. PILLAY T, Cornell M, Fox MP, Euvrard J, et al
    Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study.
    Antivir Ther. 2020 Sep 22. doi: 10.3851/IMP3371.
    >> Share

  7. CHAYANUPATKUL M, Chittmittraprap S, Pratedrat P, Chuaypen N, et al
    Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
    Antivir Ther. 2020 Sep 10. doi: 10.3851/IMP3370.
    >> Share

    June 2020
  8. SMOLDERS EJ, Te Brake LH, Burger DM
    SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
    Antivir Ther. 2020 Jun 26. doi: 10.3851/IMP3365.
    >> Share

  9. ZHANG Q, Li X, Qiao S, Shen Z, et al
    Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.
    Antivir Ther. 2020 Jun 1. doi: 10.3851/IMP3360.
    >> Share

    May 2020
  10. RAM RR, Duatschek P, Margot N, Abram M, et al
    Activation of HIV-specific CD8(+) T-cells from HIV+ donors by vesatolimod.
    Antivir Ther. 2020 May 18. doi: 10.3851/IMP3359.
    >> Share

  11. BIJKER R, Kiertiburanakul S, Kumarasamy N, Pujari S, et al
    Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.
    Antivir Ther. 2020 May 5. doi: 10.3851/IMP3358.
    >> Share

    April 2020
  12. BLACKMAN AL, Heil EL, Devanathan AS, Pandit NS, et al
    The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Antivir Ther. 2020 Apr 28. doi: 10.3851/IMP3355.
    >> Share

  13. VIVANCOS-GALLEGO MJ, Okhai H, Perez-Elias MJ, Gomez-Ayerbe C, et al
    CD4(+):CD8(+) T-cell ratio changes in people with HIV receiving antiretroviral treatment.
    Antivir Ther. 2020 Apr 27. doi: 10.3851/IMP3354.
    >> Share

  14. ALESSIO L, Onorato L, Sangiovanni V, Borrelli F, et al
    DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.
    Antivir Ther. 2020 Apr 21. doi: 10.3851/IMP3353.
    >> Share

  15. KUSEJKO K, Marzel A, Nguyen H, Chaudron SE, et al
    Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018.
    Antivir Ther. 2020 Apr 1. doi: 10.3851/IMP3347.
    >> Share

    March 2020
  16. ARENAS-PINTO A, Stohr W, Khoo S, Clarke A, et al
    Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.
    Antivir Ther. 2020 Mar 23. doi: 10.3851/IMP3340.
    >> Share

  17. CROWELL TA, Kijak GH, Sanders-Buell E, O'Sullivan AM, et al
    Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria.
    Antivir Ther. 2020 Mar 3. doi: 10.3851/IMP3342.
    >> Share

  18. BAVARO DF, Di Carlo D, Rossetti B, Bruzzone B, et al
    Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA.
    Antivir Ther. 2020 Mar 2. doi: 10.3851/IMP3349.
    >> Share

    February 2020
  19. BARANEK B, Wang S, Cheung AM, Mishra S, et al
    The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
    Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
    >> Share

    January 2020
  20. MAJEED SR, West S, Ling KH, Das M, et al
    Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Antivir Ther. 2020 Jan 14. doi: 10.3851/IMP3343.
    >> Share

    December 2019
  21. BIERHOFF M, Smolders EJ, Tarning J, Burger DM, et al
    Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.
    Antivir Ther. 2019 Dec 23. doi: 10.3851/IMP3341.
    >> Share

  22. ABGRALL S, Raho-Moussa M, Seng R, Ghislain M, et al
    Elevated risk of viral rebound on ART in migrants living in France: role of socioeconomic factors.
    Antivir Ther. 2019 Dec 23. doi: 10.3851/IMP3339.
    >> Share

    November 2019
  23. CHERU LT, Saylor CF, Fitch KV, Looby SE, et al
    Low vitamin D is associated with coronary atherosclerosis in women with HIV.
    Antivir Ther. 2019 Nov 19. doi: 10.3851/IMP3336.
    >> Share

    September 2019
  24. CHASTAIN DB, Veve MP, Wagner JL
    Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors.
    Antivir Ther. 2019 Sep 30. doi: 10.3851/IMP3335.
    >> Share

  25. AKANBI OA, Harms D, Wang B, Osundare FA, et al
    High frequency of drug resistance mutations in the HBV genome in ART-experienced HIV-coinfected patients in southwestern Nigeria.
    Antivir Ther. 2019 Sep 30. doi: 10.3851/IMP3333.
    >> Share

  26. HAWKINS KL, Montague BT, Rowan SE, Beum R, et al
    Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
    Antivir Ther. 2019 Sep 20. doi: 10.3851/IMP3330.
    >> Share

  27. VANNAPPAGARI V, Ragone L, Henegar C, van Wyk J, et al
    Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
    Antivir Ther. 2019 Sep 10. doi: 10.3851/IMP3331.
    >> Share

    August 2019
  28. ANDERSON MS, Gilmartin J, Fan L, Yee KL, et al
    No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate co-administration.
    Antivir Ther. 2019 Aug 21. doi: 10.3851/IMP3324.
    >> Share

    July 2019
  29. BALMACEDA JB, Aepfelbacher J, Belliveau O, Chaudhury CS, et al
    Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.
    Antivir Ther. 2019 Jul 30. doi: 10.3851/IMP3327.
    >> Share

    June 2019
  30. GATELL JM, Morales-Ramirez JO, Hagins DP, Thompson M, et al
    Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
    Antivir Ther. 2019 Jun 29. doi: 10.3851/IMP3323.
    >> Share

  31. VIZCARRA P, Fontecha M, Monsalvo M, Vivancos MJ, et al
    Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.
    Antivir Ther. 2019 Jun 7. doi: 10.3851/IMP3319.
    >> Share

    April 2019
  32. DEBROY P, Lake JE, Sim M, Erlandson KM, et al
    Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex.
    Antivir Ther. 2019 Apr 29. doi: 10.3851/IMP3312.
    >> Share

  33. BOERMA R, Schellekens O, Rinke de Wit TF, Wit FW, et al
    Reaching 90-90-90: outcomes of a 15-year multi-country HIV workplace programme in sub-Saharan Africa.
    Antivir Ther. 2019 Apr 24. doi: 10.3851/IMP3311.
    >> Share

  34. YOUNG J, Scherrer AU, Calmy A, Tarr PE, et al
    The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.
    Antivir Ther. 2019 Apr 15. doi: 10.3851/IMP3310.
    >> Share

  35. HUDSON FP, Mulenga L, Westfall AO, Warrier R, et al
    Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia.
    Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3299.
    >> Share

  36. ARMENIA D, Di Carlo D, Lepri AC, Calcagno A, et al
    Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
    Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309.
    >> Share

  37. ZONDAGH J, Basson AE, Achilonu I, Morris L, et al
    Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant.
    Antivir Ther. 2019 Apr 8. doi: 10.3851/IMP3308.
    >> Share

    March 2019
  38. FORD SL, Lou Y, Lewis N, Michalis K, et al
    Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Antivir Ther. 2019 Mar 21. doi: 10.3851/IMP3306.
    >> Share

  39. YOUNGER J, Raboud J, Szadkowski L, Harrigan R, et al
    Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.
    Antivir Ther. 2019 Mar 15. doi: 10.3851/IMP3302.
    >> Share

  40. BIJKER R, Kumarasamy N, Kiertiburanakul S, Pujari S, et al
    Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD).
    Antivir Ther. 2019 Mar 5. doi: 10.3851/IMP3298.
    >> Share

    February 2019
  41. PISATURO M, Starace M, Minichini C, De Pascalis S, et al
    Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment.
    Antivir Ther. 2019 Feb 13. doi: 10.3851/IMP3296.
    >> Share

  42. JARRIN I, Suarez-Garcia I, Moreno C, Tasias M, et al
    Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
    Antivir Ther. 2019 Feb 12. doi: 10.3851/IMP3297.
    >> Share

  43. HUNT GM, Ledwaba J, Kalimashe M, Salimo A, et al
    Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods.
    Antivir Ther. 2019 Feb 11. doi: 10.3851/IMP3294.
    >> Share

  44. MURTAGH R, Else LJ, Kuan KB, Khoo SH, et al
    Therapeutic drug monitoring of darunavir/ritonavir in pregnancy.
    Antivir Ther. 2019 Feb 7. doi: 10.3851/IMP3291.
    >> Share

    January 2019
  45. HALLORAN MO, Boyle C, Kehoe B, Bagkeris E, et al
    Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
    Antivir Ther. 2019 Jan 31. doi: 10.3851/IMP3293.
    >> Share

  46. HANHOFF N, Vu Q, Lang R, Gill MJ, et al
    Impact of three decades of antiretroviral therapy in a longitudinal population cohort study.
    Antivir Ther. 2019 Jan 7. doi: 10.3851/IMP3287.
    >> Share

  47. SHARMA A, Hoover DR, Shi Q, Gustafson DR, et al
    Frailty as a predictor of falls in HIV-infected and uninfected women.
    Antivir Ther. 2019 Jan 3. doi: 10.3851/IMP3286.
    >> Share


  48. 21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2019;24.
    >> Share


  49. 21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2019;24.
    >> Share

    December 2018
  50. MEDINA-MORENO S, Zapata JC, Cottrell ML, Le NM, et al
    Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.
    Antivir Ther. 2018 Dec 21. doi: 10.3851/IMP3285.
    >> Share

  51. KREITCHMANN R, Schalkwijk S, Best B, Wang J, et al
    Efavirenz pharmacokinetics during pregnancy and infant washout.
    Antivir Ther. 2018 Dec 10. doi: 10.3851/IMP3283.
    >> Share

    October 2018
  52. DUMOND JB, Greene SA, Prince HM, Chen J, et al
    Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
    Antivir Ther. 2018 Oct 30. doi: 10.3851/IMP3277.
    >> Share

  53. DENAULT JS, Cabot JF, Langlois H, Marcotte S, et al
    Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
    Antivir Ther. 2018 Oct 24. doi: 10.3851/IMP3274.
    >> Share

  54. FERRARI D, Spagnuolo V, Manca M, Bigoloni A, et al
    Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients.
    Antivir Ther. 2018 Oct 24. doi: 10.3851/IMP3275.
    >> Share

  55. SPINNER CD, Schulz S, Bauer U, Schneider J, et al
    Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: The TAF-IR Study.
    Antivir Ther. 2018 Oct 3. doi: 10.3851/IMP3271.
    >> Share

  56. CICCULLO A, Baldin G, Capetti A, Rusconi S, et al
    A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Antivir Ther. 2018 Oct 2. doi: 10.3851/IMP3270.
    >> Share

    September 2018
  57. HIRANSUTHIKUL A, Thammajaruk N, Techatanawat I, Karachot B, et al
    Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
    Antivir Ther. 2018 Sep 28. doi: 10.3851/IMP3267.
    >> Share

  58. HAVENS PL, Long D, Schuster GU, Gordon CM, et al
    Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Antivir Ther. 2018 Sep 27. doi: 10.3851/IMP3269.
    >> Share

  59. LADAK F, Socias E, Nolan S, Dong H, et al
    Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Antivir Ther. 2018 Sep 19. doi: 10.3851/IMP3265.
    >> Share

  60. VEGA AD, Hynicka LM, Claeys K, Chua JV, et al
    Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.
    Antivir Ther. 2018 Sep 7. doi: 10.3851/IMP3263.
    >> Share

    August 2018
  61. MEE TC, Aepfelbacher J, Krakora R, Chairez C, et al
    Carotid magnetic resonance imaging in persons living with HIV and 10-year atherosclerotic cardiovascular disease risk score.
    Antivir Ther. 2018 Aug 8. doi: 10.3851/IMP3258.
    >> Share

    July 2018
  62. OJHA RP, MacDonald BR, Chu TC, Fasanmi EO, et al
    Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
    Antivir Ther. 2018 Jul 3. doi: 10.3851/IMP3249.
    >> Share

    May 2018
  63. WEBER MD, Andrews E, Prince HA, Sykes C, et al
    Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
    Antivir Ther. 2018 May 1. doi: 10.3851/IMP3236.
    >> Share

    March 2018
  64. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3234.
    >> Share

  65. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3239.
    >> Share

  66. TEERAANANCHAI S, Kerr SJ, Ruxrungtham K, Avihingsanon A, et al
    Loss to follow-up and associated factors of patients through the National AIDS Program in Thailand.
    Antivir Ther. 2018 Mar 27. doi: 10.3851/IMP3233.
    >> Share

  67. VAN DAM PM, van Geffen MW, Havenith TR, Posthouwer D, et al
    Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
    Antivir Ther. 2018 Mar 13. doi: 10.3851/IMP3229.
    >> Share

    February 2018
  68. BENGTSON AM, Pence BW, Eaton EF, Edwards JK, et al
    Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.
    Antivir Ther. 2018 Feb 9. doi: 10.3851/IMP3223.
    >> Share

    January 2018
  69. BIGLIANO P, Calcagno A, Lucchini A, Audagnotto S, et al
    The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
    Antivir Ther. 2018 Jan 26. doi: 10.3851/IMP3221.
    >> Share

  70. FIORENTINO M, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, et al
    Renunciation of health care by people living with HIV in France is still associated with discrimination in health care services and social insecurity - results from the ANRS VESPA2 survey.
    Antivir Ther. 2018 Jan 23. doi: 10.3851/IMP3220.
    >> Share

  71. PETERS L, Mocroft A, Grint D, Moreno S, et al
    Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
    Antivir Ther. 2018 Jan 5. doi: 10.3851/IMP3218.
    >> Share


  72. 20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2018;23.
    >> Share

    November 2017
  73. FALUTZ J
    Frailty: is thy name.....universal? Evolving challenges of managing effectively treated older people living with HIV.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3211.
    >> Share

  74. VENUTO CS, Lim J, Messing S, Hunt PW, et al
    Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3209.
    >> Share

  75. PATEL RR, Presti R, Harrison LC, Powderly WG, et al
    Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
    Antivir Ther. 2017 Nov 23. doi: 10.3851/IMP3208.
    >> Share

    October 2017
  76. MORTIER V, Vancoillie L, Dauwe K, Staelens D, et al
    Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays.
    Antivir Ther. 2017 Oct 24. doi: 10.3851/IMP3203.
    >> Share

  77. BINDA F, Monge E, Simonetti FR, Zanchetta N, et al
    Primary HIV infection in patients with acute hepatitis B: a report of two cases.
    Antivir Ther. 2017 Oct 12. doi: 10.3851/IMP3201.
    >> Share

  78. HOPPE A, Giuliano M, Lugemwa A, Thompson JA, et al
    HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Antivir Ther. 2017 Oct 11. doi: 10.3851/IMP3200.
    >> Share

  79. ECKARD AR, O'Riordan MA, Rosebush JC, Lee ST, et al
    Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3199.
    >> Share

  80. JANTARABENJAKUL W, Anugulruengkitt S, Kasipong N, Thammajaruk N, et al
    Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198.
    >> Share

    September 2017
  81. SANTORO MM, Di Carlo D, Armenia D, Zaccarelli M, et al
    Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
    Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197.
    >> Share

  82. MARTINEZ-VEGA R, De La Mata NL, Kumarasamy N, Ly PS, et al
    Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3194.
    >> Share

  83. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Longitudinal study of falls among HIV-infected and uninfected women: the role of cognition.
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3195.
    >> Share

  84. SRINIVASA S, Lu MT, Fitch KV, Hallett TR, et al
    Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV.
    Antivir Ther. 2017 Sep 20. doi: 10.3851/IMP3193.
    >> Share

    January 2017

  85. 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2017;22.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016